This website provides information about the business field of CO.DON GmbH, which has taken over the business operations from CO.DON AG.
Information on CO.DON Aktiengesellschaft can be found at www.codon-aktiengesellschaft.de.
The mangement of CO.DON GmbH is responsible for managing the company. It acts independently and is responsible for the company meeting the objectives laid down in its Rules of Procedure. To this end it takes the necessary entrepreneurial measures, i.e. decisions on staffing, finances and strategy.
A team of division managers assists the management with the development and implementation of the company strategy.
XING ZHAO, M.D. Ph.D., has been serving as the Managing Director of CO.DON GmbH since March 2023, and as the Chairman and Global CEO of ReLive Biotechnologies since 2021.
Dr. Zhao received his Ph.D. in Regenerative Medicine and Life Sciences from Utrecht University in the Netherlands and conducted postdoctoral research fellowship at Massachusetts General Hospital and Harvard Medical School in the United States, focusing on Tissue Engineering and Regenerative Medicine for cartilage repair and regeneration.
Dr. Zhao has more than 15 years of experiences in clinical practice, scientific discovery, innovative cell product development, and investments in the biotechnological field, particularly in regenerative medicine and cell therapy. In 2010, he became an Instructor of Orthopedic Surgery at Harvard Medical School. In 2015, he served as the Head of Research and the Chairman of the Scientific Advisory Board at Vericel Corporation (NASDAQ: VCEL), a leading regenerative medicine company in the United States. As a venture capitalist, he has invested in several biotech startups in the United States.
In 2021, he founded ReLive Biotechnology, a global regenerative medicine company group focused on Orthopedics, Plastic, and Reconstructive Surgery, operating in United States, Europe, and China, which acquired all assets from CO.DON AG in January 2023.